Related Experiment Video
Updated: Jul 6, 2026

An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies
Published on: November 1, 2024
A review of the 5-HT1B/1D agonist rizatriptan: update on recent research and implications for the future
1Headache Associates and ClinExcel Research 7908 Cincinnati-Dayton Road Suite J, West Chester, OH 45069, USA. LKMannixMD@aol.com
Background:
Among the 5-HT(1B/1D) agonists or 'triptans,' which are considered first-line therapy for acute migraine, rizatriptan has emerged as one of the most efficacious.
Objective:
Several comprehensive reviews of rizatriptan are available in the literature; the aim of this paper is to review the most current research with rizatriptan.
Methods:
The scope of the review addresses current topics of clinical interest, including studies of time to pain relief, effect of early administration, use in combination with other drugs, and tolerability updates, as well as trials of rizatriptan in certain subpopulations such as patients with menstrual migraine, patients with motion sickness and pediatric patients.
Conclusion:
In the context of these newly available data, the potential for expansion of the role of rizatriptan in the clinic is evaluated.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drugs Affecting Neurotransmitter Release or Uptake

